Cequent Releases Data on RNAi Technology for Multi-Gene Targeting, Addressing Cancer Drug Resistance

The data, which were presented at this year's American Association for Cancer Research annual meeting, represent initial findings from the company's in-house effort to knock down multiple genes simultaneously and a collaboration related to multi-drug resistance of cancer cells.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.